Review ArticleReview
Open Access

Treatable inherited metabolic epilepsies

Khalid Hundallah and Brahim Tabarki
Neurosciences Journal July 2021, 26 (3) 229-235; DOI: https://doi.org/10.17712/nsj.2021.3.20210077

References

  1. 1.↵
    1. Afzal RM,
    2. Lund AM,
    3. Skovby F.
    The impact of consanguinity on the frequency of inborn errors of metabolism. Mol Genet Metab Rep 2018; 15: 6–10.
    OpenUrl
  2. 2.↵
    1. BoAli AY,
    2. Alfadhel M,
    3. Tabarki B
    . Neurometabolic disorders and congenital malformations of the central nervous system. Neurosciences (Riyadh) 2018; 23: 97–103.
    OpenUrl
  3. 3.
    1. Hakami WS,
    2. Hundallah KJ,
    3. Tabarki BM.
    Metabolic and genetic disorders mimicking cerebral palsy. Neurosciences (Riyadh) 2019; 24: 155–163.
    OpenUrl
  4. 4.↵
    1. Assi L,
    2. Saklawi Y,
    3. Karam PE,
    4. Obeid M.
    Treatable Genetic Metabolic Epilepsies. Curr Treat Options Neurol 2017; 19: 30.
    OpenUrl
  5. 5.↵
    1. Bashiri FA,
    2. Al-Sehemi MA,
    3. Hamad MH,
    4. Alshammari NR,
    5. Aljumah MA,
    6. Kentab A, et al.
    Neurodevelopmental and epilepsy outcomes of patients with infantile spasms treated in a tertiary care center. Neurosciences (Riyadh) 2021; 26: 21–25.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Alyoubi RA,
    2. Aljaafari DT,
    3. Basheikh MA,
    4. Al-Yahyawi NY,
    5. Bakry MA,
    6. BenHli NM, et al.
    The etiology and risk factors of convulsive status epilepticus in pediatric patients of tertiary center in Saudi Arabia. Neurosciences (Riyadh) 2021; 26: 26–30.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Al-Qudah AA,
    2. Albsoul-Younes A,
    3. Masri AT,
    4. AbuRahmah SK,
    5. Alabadi IA,
    6. Nafi OA, et al.
    Type and etiology of pediatric epilepsy in Jordan. Neurosciences (Riyadh) 2017; 22: 267–273.
    OpenUrl
  8. 8.↵
    1. Muthaffar OY.
    Treating epilepsy with options other than antiepileptic medications. Neurosciences (Riyadh) 2020; 25: 253–261.
    OpenUrl
  9. 9.↵
    1. Dulac O,
    2. Plecko B,
    3. Gataullina S,
    4. Wolf NI.
    Occasional seizures, epilepsy, and inborn errors of metabolism. Lancet Neurol 2014; 13: 727–739.
    OpenUrl
  10. 10.↵
    1. Al-Saman AS,
    2. Rizk TM.
    A case of extreme prematurity and delayed diagnosis of pyridoxine-dependent epilepsy. Neurosciences (Riyadh) 2012; 17: 371–373.
    OpenUrlPubMed
  11. 11.↵
    1. Coughlin CR 2nd.,
    2. Tseng LA,
    3. Abdenur JE,
    4. Ashmore C,
    5. Boemer F,
    6. Bok LA, et al.
    Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to alpha-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2021; 44: 178–192.
    OpenUrl
  12. 12.↵
    1. Gallagher RC,
    2. Van Hove JL,
    3. Scharer G,
    4. Hyland K,
    5. Plecko B,
    6. Waters PJ, et al.
    Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009; 65: 550–556.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Alghamdi M,
    2. Bashiri FA,
    3. Abdelhakim M,
    4. Adly N,
    5. Jamjoom DZ,
    6. Sumaily KM, et al.
    Phenotypic and molecular spectrum of pyridoxamine-5’-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5’-phosphate oxidase deficiency. Clin Genet 2021; 99: 99–110.
    OpenUrl
  14. 14.↵
    1. Sayegh LN,
    2. Daher RT,
    3. Bassyouni A,
    4. Karam PE.
    Diagnosis and management of symptomatic profound biotinidase deficiency in a tertiary care center in Lebanon. Clin Biochem 2020; 86: 52–55.
    OpenUrl
  15. 15.↵
    1. Van Karnebeek CDM,
    2. Sayson B,
    3. Lee JJY,
    4. Tseng LA,
    5. Blau N,
    6. Horvath GA, et al.
    Metabolic Evaluation of Epilepsy: A Diagnostic Algorithm With Focus on Treatable Conditions. Front Neurol 2018; 9: 1016.
    OpenUrlCrossRef
  16. 16.↵
    1. Klepper J,
    2. Akman C,
    3. Armeno M,
    4. Auvin S,
    5. Cervenka M,
    6. Cross HJ, et al.
    Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 2020; 5: 354–365.
    OpenUrlCrossRef
  17. 17.↵
    1. Tabarki B,
    2. Al-Shafi S,
    3. Al-Shahwan S,
    4. Azmat Z,
    5. Al-Hashem A,
    6. Al-Adwani N, et al.
    Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013; 80: 261–267.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. El-Hattab AW.
    Serine biosynthesis and transport defects. Mol Genet Metab 2016; 118: 153–159.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Schwahn BC,
    2. Van Spronsen FJ,
    3. Belaidi AA,
    4. Bowhay S,
    5. Christodoulou J,
    6. Derks TG, et al.
    Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet 2015; 386: 1955–1963.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. He R,
    2. Mo R,
    3. Shen M,
    4. Kang L,
    5. Song J,
    6. Liu Y, et al.
    Variable phenotypes and outcomes associated with the MMACHC c.609G>A homologous mutation: long term follow-up in a large cohort of cases. Orphanet J Rare Dis 2020;15:200.
    OpenUrl
  21. 21.↵
    1. Al-Baradie RS,
    2. Chudary MW.
    Diagnosis and management of cerebral folate deficiency. Neurosciences (Riyadh) 2014; 19: 312–316.
    OpenUrl
  22. 22.↵
    1. Fons C,
    2. Campistol J.
    Creatine Defects and Central Nervous System. Semin Pediatr Neurol 2016; 23: 285–289.
    OpenUrl
  23. 23.↵
    1. Letourneau LR,
    2. Greeley SAW.
    Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations. Curr Diab Rep 2019; 19: 52.
    OpenUrl
  24. 24.↵
    1. Ninković D,
    2. Sarnavka V,
    3. Bašnec A,
    4. Ćuk M,
    5. Ramadža DP,
    6. Fumić K, et al.
    Hyperinsulinism-hyperammonemia syndrome: a de novo mutation of the GLUD1 gene in twins and a review of the literature. J Pediatr Endocrinol Metab 2016; 29: 1083–1088.
    OpenUrl
  25. 25.↵
    1. Opladen T,
    2. López-Laso E,
    3. Cortès-Saladelafont E,
    4. Pearson TS,
    5. Sivri HS,
    6. Yildiz Y, et al.
    Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis 2020; 15: 126.
    OpenUrl
  26. 26.↵
    1. Matricardi S,
    2. Canafoglia L,
    3. Ardissone A,
    4. Moroni I,
    5. Ragona F,
    6. Ghezzi D, et al.
    Epileptic phenotypes in children with early-onset mitochondrial diseases. Acta Neurol Scand 2019; 140: 184–193.
    OpenUrl
  27. 27.↵
    1. Horino A,
    2. Kawawaki H,
    3. Fukuoka M,
    4. Tsuji H,
    5. Hattori Y,
    6. Inoue T, et al.
    A case of succinic semialdehyde dehydrogenase deficiency with status epilepticus and rapid regression. Brain Dev 2016; 38: 866–870.
    OpenUrl
  28. 28.↵
    1. Mazurkiewicz-Bełdzińska M,
    2. Del Toro M,
    3. Haliloğlu G,
    4. Huidekoper HH,
    5. Kravljanac R,
    6. Mühlhausen C, et al.
    Managing CLN2 disease: A treatable neurodegenerative condition among other treatable early childhood epilepsies. Expert Rev Neurother 2021; 1–8.
  29. 29.↵
    1. Mathis D,
    2. Beese K,
    3. Rüegg C,
    4. Plecko B,
    5. Hersberger M.
    LC-MS/MS method for the differential diagnosis of treatable early onset inherited metabolic epilepsies. J Inherit Metab Dis 2020; 43: 1102–1111.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section